Trade War

German medicine standards reach Lesotho's cannabis drying and export route

German guidance puts manufacturing controls near the harvest. Lesotho's exporters also depend on an approved transit route through South Africa to connect production with overseas buyers.

Companies and supply chains 17 November 2026

German guidance updated on 18 August 2026 places controls on cannabis drying that matter to Lesotho's medicinal-cannabis exporters. Hesse's health authority treats controlled drying as a critical manufacturing step, with consequences for where processing takes place before flowers reach Germany.1

The requirement reaches back along the supply chain. Meeting a buyer's specification at the final destination does not by itself establish that earlier manufacturing stages followed the required procedures.

Quality controls begin near the harvest

Hesse's authority says timely processing, including drying and trimming, should meet good manufacturing practice at the harvest location unless loss of quality can conclusively be excluded. It describes drying as:

kritischer Herstellungsschritt

a critical manufacturing step.1

The guidance also requires an import certificate for each supplier in a third country and a diagram identifying which facilities perform which operations. These are the state regulator's interpretation and enforcement requirements, rather than a new German ban on Lesotho's products.1

A commercial link already exists

Lesotho producer MG Health and Germany's Canify announced a proposed merger in March. Their company statement said MG Health had supplied Canify with medicinal cannabis flowers since the final quarter of 2024. It described manufacturing and extraction in Lesotho feeding pharmaceutical processing and distribution through Canify's pharmacy network. This provides company-reported evidence of an operating supply relationship, rather than merely a plan to begin exporting.2

The announcement presented EU manufacturing certification as central to that model. It also made completion of the merger conditional on final contracts and regulatory approvals. The statement therefore supports the existence of the supply arrangement and the proposed integration, but does not establish that the transaction has subsequently closed or that additional production has materialised.2

Transit permission is another requirement

A separate regional record shows why pharmaceutical compliance is only part of getting output to market. In a complaint filed with the COMESA-EAC-SADC trade-barrier system, MG Health reported that South African officials returned a truck because Maseru Bridge was not an authorised entry point for the cargo. The company said flying consignments onward to Johannesburg's OR Tambo airport instead would require multiple flights and raise costs.3

The register marks the complaint resolved on 15 April 2026. Its status note cites an amendment allowing medicine or scheduled substances in transit through Maseru, provided the South African authority is notified and approves the intended importation. The record establishes a conditional regulatory route; it does not publish a subsequent shipment total or a quantified saving.3

Lesotho's development corporation is promoting investment in drying, trimming, packaging and analytical laboratories, alongside extraction and finished formulations. Its investment page explicitly tells facilities to meet the certification requirements of their target markets. These are investment opportunities, not evidence that every proposed facility has been built. Whether new projects secure certification for their actual processing operations will determine how much additional cultivation can feed the export route.4

Sources

  1. Hessian State Office for Health and Care. Merkblatt: Einfuhr, Herstellung und Vertrieb von Cannabisblüten [Guidance: import, manufacture and distribution of cannabis flowers]. 18 August 2026Germany's camp · state pharmaceutical regulator guidance · in German
  2. Canify AG / EQS News. Fusion mit Wirkung: MG Health und Canify formen einen international führenden Anbieter für medizinisches Cannabis [Merger with impact: MG Health and Canify form an international leading medical cannabis provider]. 12 March 2026Industry camp · company announcement · in German
  3. COMESA-EAC-SADC Non-Tariff Barriers reporting mechanism. Complaint NTB-001-180: medical cannabis transit at Maseru Bridge. updated 15 April 2026Independent camp · complaint and resolution register
  4. Lesotho National Development Corporation. Medicinal Cannabis. undated, accessed 17 November 2026Lesotho's camp · investment agency sector prospectus

All articles